Exco InTouch, the leading provider of patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, today announced that it has now formally received U.S.- EU Safe Harbor Framework and U.S.- Swiss Safe Harbor Framework Self Certification status by the U.S. Department of Commerce’s International Trade Administration (ITA). The designation certifies that Exco InTouch’s practices meet or exceed the data privacy and security standards outlined by The European Commission’s Directive on data protection.
The U.S. Department of Commerce, in consultation with the European Commission, developed the Safe Harbor framework in order to bridge the gap between EU/Switzerland and U.S. approaches to privacy protection and provide a streamlined means for U.S. organisations to comply with the Commission’s Directive. In order to be recognised for the certification, Exco InTouch has demonstrated that its customer privacy procedures comply with the seven ‘Safe Harbor Privacy Principles’ which cover notice, choice, transfers to third parties, access, security, data integrity and enforcement. As a result, Exco InTouch’s customers, for whom the company provides mobile and digital patient engagement solutions, can be reassured that their programs comply with these stringent privacy and security safeguards.
“Protecting the privacy and confidentiality of personal information has always been, and will remain, the highest priority for Exco InTouch,” says Mike Hansen, COO and Co-Founder of Exco InTouch. “The U.S. – EU and US – Swiss Safe Harbor Certification will not only help to streamline our data transfer processes between the EU/Switzerland and U.S, but will also provide our customers with further reassurance that we are fully compliant with the highest standards of data protection.”
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.